

DAFTAR PUSTAKA

- Abraldes, J.G., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, J.C., Bosch, J., 2009. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology*. 136(5):1651-8.
- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., *et al.*, 2016. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology*, 150, 1160–1170.
- Akçiçek, F., Ok, E., Duman, S., Kürsad, S., Unsal, A., Alev, M., *et al.*, 1996. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. *Adv Perit Dial.*, 12, 261-5.
- Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., The National Lipid Association's Statin Safety Task Force., 2014. An assesment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipidol*. May-Jun;8(3 Suppl): S47-57.
- Benyon, R.C., Iredale, J.P., 2000. Is liver fibrosis reversible? *Gut*, 46, 443-446.
- Calderon, M.R., Cubeddu, L.X., Goldber, R.B., Schiff, E.R., 2010. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. *Mayo Clin Proc*. 85(4):349-56.
- Catherine, A. P., Sanjiv, C., 1998. Chirrosis and portal hipertension *In: S. Lawrence dan B. Emmet (eds.) Handbook of liver disease*.
- Chung, R. T. dan Podolsky, D. K. 2005. Chirrosis and it complication. *In: D. L. Kasper, A. S. Fauci, D. L. Longo, et al. (eds.) Harrison' principles of internal medicine*. New York: McGraw-Hill. 234-265
- Dahlan, M.S. 2009. Besar Sampel dalam Penelitian. Jakarta: Penerbit Salemba Medika. Jakarta
- Dale, K.M., White, C.M., Henyan, N.N., 2007. Impact of statin dosing intensity on transaminase and creatinin kinase. *Am J Med*. 120(8), 706-712.
- D'Amico, G., Garcia-Pagan, J.C., Luca, A., Bosch, J., 2006. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. *Gastroenterology*;131:1611-24.
- Dancygier, H^a. 2010. Clinical scoring systems. *In: H. Dancygier (ed.) Clinical Hepatology*. Verlag Berlin Heidelberg. springer: 289-290.
- Dancygier, H^b. 2010. Liver Cirrhosis. *In: H. Dancygier (ed.) Clinical Hepatology*. Verlag Berlin Heidelberg: springer, 949-966.
- Dietrich, C. F. 2010. Ultrasonography. *In: H. Dancygier (ed.) Clinical Hepatology*. Verlag Berlin Heidelberg. springer: 359-404.

- Foucher, J., Chanteloup, E., Vergniol, J., Caste'ra, L., Le Bail, B., Adhoute, X., *et al.* 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*, 55, 403–408.
- Garcia-Pagan, J.C., Villanueva, C., Albillos, A., *et al.*, 2009. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: A multicenter randomized controlled trial. *Gut*, 58:1144 - 50.
- Ghadir, M. R., Riahin, A. A., Havaspour, A., Nooranipour, M. dan Habibinejad, A. A. 2010. The Relationship between Lipid Profile and Severity of Liver Damage in Cirrhotic Patients. *Hepat Mon*, 10: 285 - 288.
- Gillet, R.C., Morrell, A., 2011. Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicity *Am Fam Physician*, 83(6): 711-716.
- Gressner, A.M., Weiskirchen, R., 2006. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF- β as major players and therapeutic targets. *J. Cell. Mol. Med.* Vol 10, No 1, pp. 76-99
- Heidelbaugh, J.J., Sherbondy, M., 2006. Cirrhosis and chronic liver failure: part II. Complications and treatment. *Am Fam Physician*. 74(5): 767-76.
- Hernandez-Perera, O., Perez-Sala, D., Soria, E., Lamas, S., 2000. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. *Circ. Res.*, 87, 616–622.
- Hernomo, O. K., 2007. Sirosis Hati. In: S. Ali, A. Nurul, A. L. Laurentius, *et al.* (eds.) *Buku Ajar Ilmu Penyakit Hati*. Jaya Abadi. 102-112
- Ito, D., Ito, O., Mori, N., Muroya, Y., Cao, P.Y., Takashima, K., *et al.*, 2010. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. *Journal Hypertensi*, 28(11): 2278-88.
- Kamath, P. S., Kim, W. R., 2007. The Model for End-Stage Liver Disease (MELD). *Hepatology*, 45, 797–805.
- Katzung, BG., 2002. Farmakologi Dasar dan Klinik, edisi II. Jakarta, *Salemba Medika*, 671-678.
- Kumar, S., Grace, ND., Qamar, A. A., 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Dig Dis Sci*, 59, 1958–1965.
- Kusumastuti, D., 2012. Perbedaan Rerata Pemanjangan Diatesis Hemoragik pada Penderita Sirosis Hati yang Mengalami Pendarahan dan yang Tidak Mengalami Pendarahan Varises Esofagus. Tesis: Fakultas Kedokteran Universitas Gadjah Mada.
- Kusumobroto, H., Adi, P., Setiawan, PB., Maimunah, U., 2007. Panduan penatalaksanaan perdarahan varises pada sirosis hati. *Dalam: Konsensus nasional Perkumpulan Gastroenterologi Indonesia*. Surabaya; p.1-29.
- Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., *et al.* 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *The American Journal of Cardiology*, 93: 152–160.

- Laufs, U., Gertz, K., Huang, P., Nickenig, G., Bohm, M., Dirnagl, U., Endres, M. 2000. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. *Stroke AHA Journals*, 31: 2437-49.
- Lochs, H., Plauth, M., 1999. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care*, 4, 345-349.
- Maruyama, H., Yokosuka, O., 2012. Pathophysiology of Portal Hypertension and Esophageal Varices. *International Journal of Hepatology*, Vol.2012.
- Mason, J.C., 2003. Statins and their role in vascular protection. *Clinical Science*, 105, 251-266.
- McCormick, P. 2011. Hepatic Cirrhosis. In A John Wiley & Sons: *Sherlock's Diseases Of The Liver And Biliary System* 12Th Ed., Ltd, Publication, 103-117.
- McGirt, M.J., Lynch, J.R., Parra, A., Sheng, H., Pearlstein, R.D., Laskowitz, D.T., *et al.*, 2002. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. *Stroke*, 33: 2950-2956.
- Nangle, M.R., Cotter, M.A., Cameron, N.E., 2003. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice : relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. *Diabetes*, 52: 2396-2402.
- Nurdjanah, S. 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds.) *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: InternaPublishing: 668-673.
- Philips, C. A., Sahney, A., 2016. Oesophageal and gastric varices: historical aspects, classification and grading: everyting in one place. *Gastroenterology Report*, 1-10.
- Pollo-Flores, P., Soldan, M., Santos, U.C., *et al.*, 2015. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. *Dig Liver Dis*.xxx.xxx-xxx.
- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the oesophagus for bleeding oesophageal varices. *The British journal of surgery*, 60 (8), 646-9.
- Rajamannan, N.M., Subramaniam, M., Stock, S.R., Stone, N.J., Springett, M., Ignatiev, K.I., *et al.*, 2005. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. *Heart Journal*, 91: 806-810.
- Rodriguez, V.J., Sanchez, G.E., Santamaria, B., Sanchez, L.E., Rodrigues, D.R., Blanco, C.L.M., Egido, J., Ortiz, A., Ruia, O.M., 2008. Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. *Plos One*, 3(12):e3959.
- Rombouts, K, Kisanga, E., Hellemans, K., Wielant, A., Schuppan, D., Geerts, A., 2003. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. *J Hepatol*. May;38(5):564-72.

- Rossoni, L.V., Wareing, M., Wenceslau, C.F., Al-Abri, M., Cobb, C., Austin, C., 2011. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. *Clinical Science*, 121: 449–458.
- Sherlock, S., Dooley, J. D., 2002. Hepatik Cirrhosis. In: S. Sherlock dan J. D. Dooley (eds.) *Diseases of the Liver and Biliary System* Eleventh ed.: Blackwell Science: 190-198
- Shirin, H., Sharvit, E., Aeed, H., Gavish, D., Bruck, R., 2013. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. *World J Gastroenterol* January 14; 19(2): 241-248
- Strassburg, C. P. 2010. Percutaneous Liver Biopsy. In: H. Dancygier (ed.) *Clinical Hepatology*. Verlag Berlin Heidelberg: springer.
- Sutadi, S. M., 2003. *Sirosis Hepatis*. Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Sumatera Utara.
- Tandon, V., Bano, G., Khajuria, V., Parihar, A., Gupta, S., et al., 2004. Pleiotropic effect of statins. *Indian J Pharmacol*.37(2):77-85.
- Thomas, R. R. dan Ahsan, M. B., 2001. Preventive strategies in chronic liver disease. *American Family Physician* 64, 1555-1560.
- Trocha, M., Merwid-L, A., Szuba, A., Chlebda, E., Pieoeniewska, M., Sozański, T., et al., 2010. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. *Pharmacological Reports*, 62: 343-351.
- Tsao, G.G., Sanyal, A.J., Grace, N.G., 2007. AASLD Guidelines: Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology*: 46: 922-938.
- Uschner, F.E., Ranabhat, G., Choi, S.S., et al., 2015. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. *Sci Rep*;5:14573.
- Vidyani et al., 2011. Faktor Risiko Terkait Pendarahan Varises Esofagus Berulang pada Penderita Sirosis Hati. *Jurnal Indonesian Medical Association* 61(10): 417-424.
- Witztum, J.L., 1996. Drugs Used in the Treatment of Hyperlipoproteinemias. In: Molinoff, P.B., and Ruddon, R.W. (editor). *Goodman & Gilman's The Pharmacological Basic Of Therapeutics*. Edisi 9. New York : McGraw Hill, Inc., 887.
- Wolf, D. C., 2009. *Cirrhosis* [Online]. Available at: <http://emedicine.medscape.com/article/185856-overview> [Accessed 28 november 2016].
- Yang, H., Choi, M.J., Wen, H., Kwon, H.N., Jung, K.H., Hong, S.W., Kim, J.M., Hong, S.S., Park, S., 2011. An Effective Assessment of Simvastatin-Induced Toxicity with NMR-Based Metabonomics Approach Published: February 22, <http://dx.doi.org/10.1371/journal.pone.0016641>

Zafra, C., Abraldes, J.G., Turnes, J., Berzigotti, A., Fernández, M., Garcia-Pagán, J.C., Rodés, J., Bosch, J., 2004. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. *Gastroenterology*. Mar;126(3):749-55.